Whether cleaning up plaques in AD or mopping up debris in the wake of a stroke, microglia get by with a little help from TREM2.
Large consortium releases epigenome profiles of 111 different tissues. They are already yielding insight into the immune system’s role in Alzheimer’s disease.
Skin side effect under investigation.
Routine cognitive screening could help doctors spot people at risk of dementia. Two new tests could make screening more accessible.
A debate has sprung up in response to a Cell essay arguing that the baby was thrown out with the bathwater when a γ-secretase inhibitor failed in Phase 3.
Alzheimer's Research UK has funded institutes at three universities to turn academic ideas into drug candidates.
Two studies suggest that the anti-inflammatory interleukin-10 prevents efficient plaque clearance and worsens AD-like pathology in mice.
Hollywood has discovered the narrative power of neurodegenerative diseases.
When the γ-secretase inhibitor semagacestat sank ingloriously over side effects and cognitive worsening in Phase 3 testing, small-molecule drug developers tossed the target onto the scrap heap and turned their focus and resources toward BACE. But wait—semagacestat is history, but has the field at large learned enough from the data to warrant giving up on γ-secretase, too? Prompted by Bart De Strooper, leading scientists in academia and industry are debating the question. Read De Strooper’s article, generously made available by Cell Press. Ponder the extensive commentary on Alzforum, consider the detailed reply by Eric Siemers and colleagues at Eli Lilly and Company, and join the conversation.
What distinguishes a hippocampal neuron from a substantia nigra one—or from a liver or blood cell, for that matter? It’s all in the parts of the genetic code they choose to read or ignore, determined by epigenetic markers like histone methylation. Now scientists can read the epigenome too, in a publicly available set of reference data from 111 different tissue types. The data suggest that changes to gene expression in immune cells initiate Alzheimer’s disease.
The National Institutes of Health hosted a meeting earlier this month as leaders in Alzheimer’s and other diseases met in Bethesda, Maryland, for the AD Research Summit 2015. The first such meeting since the National Plan to Address Alzheimer’s Disease was put into action in 2012, the summit served to spur the field on toward the goal of preventing and effectively treating Alzheimer’s by 2025. Over the two-day meeting, researchers proposed ways of finding therapeutic targets outside of the familiar Aβ and tau fields. Data sharing was a big theme for this goal. Speakers also weighed in on how to enlarge patient cohorts, capture better phenotypic data, engage minority communities, and harness citizen science to analyze vast quantities of data. Read Gwyneth Dickey Zakaib’s two-part series.
Berislav Zlokovic's recent Neuron paper set the stage for Alzforum’s latest Webinar, "Leaky Blood-Brain Barrier: A Harbinger of Alzheimer's?" Borrowing an MRI technique from oncology to measure the permeability of the BBB, Zlokovic and colleagues reported an age-related breakdown of the barrier in older adults and in people with mild cognitive impairment. Tammie Benzinger, Roderick Corriveau, and Costantino Iadecola joined Zlokovic for a panel discussion. If you missed the Webinar, you can catch it all online. The recording and slide presentation are now available.
- Charles Glabe on Semagacestat Failure Analysis: Should γ-Secretase Remain a Target?
- Michael Heneka on TREM2 Lipid Sensing Sustains Microglial Response in an Alzheimer’s Disease Model
- Rebecca Sims on Consortium Debuts Biggest Set of Human Epigenomes To Date
- Eric Siemers, Ronald DeMattos, Robert Dean and Karen Sundell on Lessons from a failed γ-secretase Alzheimer trial.
- Ammar Al-Chalabi on Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease.
- Nitin Saksena on A neuroprotective role for microRNA miR-1000 mediated by limiting glutamate excitotoxicity.
- Michael van Es on Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.